$CSTAF
Constellation Acquisition Corp I

2024 Q1 Form 10-Q Financial Statement

#000121390024043629 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q1 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $788.3K $3.560M
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $55.00K $1.315M $65.00K
YoY Change -95.82% 468.32% -94.13%
Operating Profit -$788.3K -$1.315M -$3.560M
YoY Change -40.05% 468.34% 221.71%
Interest Expense $389.0K $328.3K $3.026M
YoY Change 18.49% 7481.52% -32.36%
% of Operating Profit
Other Income/Expense, Net $294.2K $328.3K $3.200M
YoY Change -10.38% -93.08% -77.12%
Pretax Income -$494.2K -$986.8K -$360.5K
YoY Change -49.93% -121.85% -102.8%
Income Tax
% Of Pretax Income
Net Earnings -$494.2K -$986.8K -$360.5K
YoY Change -49.93% -121.85% -102.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.05 -$0.05 -$0.03
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q1 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.860K $5.860K $3.540K
YoY Change -34.13% -94.04% -90.62%
Cash & Equivalents $3.858K $5.864K
Short-Term Investments
Other Short-Term Assets $126.8K $405.4K $33.41K
YoY Change -68.71% 19.33% -0.12%
Inventory
Prepaid Expenses $126.9K $405.4K
Receivables
Other Receivables
Total Short-Term Assets $130.7K $411.2K $36.95K
YoY Change -68.21% -6.12% -48.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $26.74M $46.85M $49.86M
YoY Change -42.93% -84.89% -84.15%
Other Assets $0.00
YoY Change
Total Long-Term Assets $26.74M $46.85M $49.86M
YoY Change -42.93% -84.89% -84.15%
TOTAL ASSETS
Total Short-Term Assets $130.7K $411.2K $36.95K
Total Long-Term Assets $26.74M $46.85M $49.86M
Total Assets $26.87M $47.26M $49.89M
YoY Change -43.15% -84.78% -84.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $30.00K
YoY Change
Accrued Expenses $3.578M $1.751M $3.081M
YoY Change 104.36% 141.71% 216.29%
Deferred Revenue
YoY Change
Short-Term Debt $3.878M $968.9K $3.358M
YoY Change 300.27% 1197.71%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.606M $2.750M $6.559M
YoY Change 176.62% 279.62% 432.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $11.25M $12.34M $11.15M
YoY Change -8.86% -23.32% -1.53%
Total Long-Term Liabilities $11.25M $12.34M $11.15M
YoY Change -8.86% -23.32% -1.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.606M $2.750M $6.559M
Total Long-Term Liabilities $11.25M $12.34M $11.15M
Total Liabilities $18.85M $15.09M $17.71M
YoY Change 24.94% -10.27% 41.03%
SHAREHOLDERS EQUITY
Retained Earnings -$18.72M -$14.68M
YoY Change 27.55%
Common Stock $1.597M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$18.72M -$14.68M $32.19M
YoY Change
Total Liabilities & Shareholders Equity $26.87M $47.26M $49.89M
YoY Change -43.15% -84.78% -84.14%

Cashflow Statement

Concept 2024 Q1 2023 Q1 2023
OPERATING ACTIVITIES
Net Income -$494.2K -$986.8K -$360.5K
YoY Change -49.93% -121.85% -102.8%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$354.7K -$880.3K -$1.334M
YoY Change -59.71% 603.96% 200.09%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $23.51M $269.0M $267.7M
YoY Change -91.26%
Cash From Investing Activities $23.51M $269.0M $267.7M
YoY Change -91.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $23.67M $269.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$23.15M -$268.2M -$266.4M
YoY Change -91.37% -103039.3%
NET CHANGE
Cash From Operating Activities -$354.7K -$880.3K -$1.334M
Cash From Investing Activities $23.51M $269.0M $267.7M
Cash From Financing Activities -$23.15M -$268.2M -$266.4M
Net Change In Cash $317.00 -$31.88K -$34.20K
YoY Change -100.99% -81.58%
FREE CASH FLOW
Cash From Operating Activities -$354.7K -$880.3K -$1.334M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39945
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
CONSTELLATION ACQUISITION CORP I
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1574835
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Park Avenue
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
32nd Floor
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10166
CY2024Q1 dei City Area Code
CityAreaCode
(646)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
585-8975
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
true
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3858 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3541 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
126852 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
33411 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
130710 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
36952 usd
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
26740054 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
49857596 usd
CY2024Q1 us-gaap Assets
Assets
26870764 usd
CY2023Q4 us-gaap Assets
Assets
49894548 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3577757 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3080658 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7605965 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6558866 usd
CY2024Q1 csta Deferred Underwriting Fees
DeferredUnderwritingFees
10850000 usd
CY2023Q4 csta Deferred Underwriting Fees
DeferredUnderwritingFees
10850000 usd
CY2024Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
394999 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
300199 usd
CY2024Q1 us-gaap Liabilities
Liabilities
18850964 usd
CY2023Q4 us-gaap Liabilities
Liabilities
17709065 usd
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
26740054 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
49857596 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18721029 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17672888 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-18720254 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-17672113 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26870764 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49894548 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
788341 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1315104 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-788341 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1315104 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
388991 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1369906 usd
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
94800 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1014360 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
294191 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
355546 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-494150 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-959558 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-17672113 usd
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
553991 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-494150 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-18720254 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-12485579 usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1819906 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-959558 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-15265043 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-494150 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-959558 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
388991 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1369906 usd
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
94800 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1014360 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
93441 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
371911 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
497099 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
776708 usd
CY2024Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
30000 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
30000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-354683 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-880307 usd
CY2024Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
165000 usd
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
450000 usd
CY2024Q1 us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
23671533 usd
CY2023Q1 us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
269485746 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23506533 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
269035746 usd
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
31572 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
470000 usd
CY2024Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
50000 usd
CY2023Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1330000 usd
CY2024Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
23671533 usd
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
269485746 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-23151533 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-268187318 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
317 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-31879 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3541 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37743 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3858 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5864 usd
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
310000000 usd
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10
CY2021Q1 us-gaap Maturity Of Time Deposits
MaturityOfTimeDeposits
P185D
CY2021Q1 csta Percentage Of Public Shareholding To Be Redeemed In Case Business Combination Is Not Consummated
PercentageOfPublicShareholdingToBeRedeemedInCaseBusinessCombinationIsNotConsummated
1 pure
CY2024Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10
CY2023Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
150000 usd
CY2023Q1 us-gaap Sponsor Fees
SponsorFees
3000000 usd
CY2024Q1 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
26506157 shares
CY2024Q1 csta Trust Account Price Per Share
TrustAccountPricePerShare
10.17
CY2023Q4 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
11.5
CY2024Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
5000001 usd
CY2024Q2 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
9967684 shares
CY2024Q1 us-gaap Noninterest Bearing Deposit Liabilities
NoninterestBearingDepositLiabilities
55000 usd
CY2024Q1 us-gaap Deposits
Deposits
55000 usd
CY2024Q1 us-gaap Time Deposits
TimeDeposits
605000 usd
CY2024Q1 csta Operating Bank Account
OperatingBankAccount
3858 usd
CY2024Q1 csta Working Capital Deficit
WorkingCapitalDeficit
7475255 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these unaudited condensed financial statements is the determination of the fair value of the warrant liability and convertible promissory notes. Such estimates may be subject to change as more current information becomes available and, accordingly, the actual results could differ significantly from those estimates.</p>
CY2024Q1 csta Proceeds From Cash Withdrawn From Trust Account In Connection With Redemption
ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption
23671533 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts and a Trust Account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition.</p>
CY2024Q1 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000 usd
CY2024Q1 csta Transaction Costs
TransactionCosts
17586741 usd
CY2024Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
2367684 shares
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
4493843 shares
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
314517268 usd
CY2023 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
269485746 usd
CY2023 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
4826074 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
49857596 usd
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
553991 usd
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
23671533 usd
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
26740054 usd
CY2024Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2024Q1 csta Issue Price Or Effective Issue Price
IssuePriceOrEffectiveIssuePrice
9.2
CY2024Q1 csta Market Value Percentage
MarketValuePercentage
1 pure
CY2024Q1 csta Newly Issued Price Percentage
NewlyIssuedPricePercentage
1.80 pure
CY2024Q1 csta Class Of Warrant Or Right Redemption Of Warrants Or Rights Stock Price Trigger
ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger
18
CY2024Q1 csta Redemption Price Per Warrant
RedemptionPricePerWarrant
0.01
CY2024Q1 csta Warrants Price Per Shares
WarrantsPricePerShares
0.1
CY2024Q1 csta Prior Written Notice Of Redemption Term
PriorWrittenNoticeOfRedemptionTerm
P30D
CY2024Q1 csta Redeem Warrants Per Share
RedeemWarrantsPerShare
0.1
CY2024Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10
CY2024Q1 us-gaap Net Asset Value Per Share
NetAssetValuePerShare
18
CY2024Q1 csta Number Of Trading Days
NumberOfTradingDays
P10D
CY2024Q1 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
1125000 shares
CY2024Q1 csta Initial Business Combination
InitialBusinessCombination
P1Y
CY2020Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1300 usd
CY2021Q1 csta Additional Debt Instrument Of Face Amount
AdditionalDebtInstrumentOfFaceAmount
88540 usd
CY2021Q1 us-gaap Debt Instrument Repaid Principal
DebtInstrumentRepaidPrincipal
89840 usd
CY2021Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
699999 usd
CY2022Q4 csta Unsecured Promissory Note Principal Amount
UnsecuredPromissoryNotePrincipalAmount
258780 usd
CY2024Q1 csta Unsecured Promissory Note Principal Amount
UnsecuredPromissoryNotePrincipalAmount
1660000 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
470000 usd
CY2024Q1 csta Outstanding Promissory Notes
OutstandingPromissoryNotes
697208 usd
CY2023Q4 csta Outstanding Promissory Notes
OutstandingPromissoryNotes
227208 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
55000 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
65000 usd
CY2021Q1 us-gaap Payment For Administrative Fees
PaymentForAdministrativeFees
10000 usd
CY2024Q1 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
30000 usd
CY2023Q1 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
30000 usd
CY2023 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
120000 usd
CY2024Q1 csta Working Capital Loans
WorkingCapitalLoans
1500000 usd
CY2024Q1 csta Price Paid Per Warrant
PricePaidPerWarrant
1.5
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
227208 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
227208 usd
CY2024Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
150000 usd
CY2023Q1 us-gaap Debt Instrument Issued Principal
DebtInstrumentIssuedPrincipal
450000 usd
CY2023Q1 us-gaap Debt Instrument Repaid Principal
DebtInstrumentRepaidPrincipal
1270000 usd
CY2024Q1 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
3181000 usd
CY2023Q4 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
3131000 usd
CY2024Q1 csta Deferred Underwriting Fees Payable
DeferredUnderwritingFeesPayable
10850000 usd
CY2023Q1 us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
3000000 usd
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 csta Ordinary Shares Outstanding Percentage
OrdinarySharesOutstandingPercentage
0.20 pure
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
CY2024Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001834032

Files In Submission

Name View Source Status
csta-20240331_cal.xml Edgar Link unprocessable
ea0205683-10q_constella1_htm.xml Edgar Link completed
0001213900-24-043629-index-headers.html Edgar Link pending
0001213900-24-043629-index.html Edgar Link pending
0001213900-24-043629.txt Edgar Link pending
0001213900-24-043629-xbrl.zip Edgar Link pending
csta-20240331.xsd Edgar Link pending
ea0205683-10q_constella1.htm Edgar Link pending
ea020568301ex31-1_constella1.htm Edgar Link pending
ea020568301ex31-2_constella1.htm Edgar Link pending
ea020568301ex32-1_constella1.htm Edgar Link pending
ea020568301ex32-2_constella1.htm Edgar Link pending
csta-20240331_def.xml Edgar Link unprocessable
csta-20240331_lab.xml Edgar Link unprocessable
csta-20240331_pre.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable